Virtu Financial LLC lifted its position in shares of Trevena Inc (NASDAQ:TRVN) by 1,546.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 191,701 shares of the biopharmaceutical company’s stock after buying an additional 180,055 shares during the period. Virtu Financial LLC’s holdings in Trevena were worth $307,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in shares of Trevena by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 980,440 shares of the biopharmaceutical company’s stock worth $2,500,000 after buying an additional 268,825 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Trevena by 15.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock worth $4,191,000 after buying an additional 238,089 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Trevena by 15.8% during the 2nd quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock worth $1,318,000 after buying an additional 77,934 shares during the last quarter. Bourgeon Capital Management LLC increased its holdings in shares of Trevena by 59.3% during the 4th quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 51,300 shares during the last quarter. Finally, Northpointe Capital LLC increased its holdings in shares of Trevena by 38.2% during the 4th quarter. Northpointe Capital LLC now owns 1,772,557 shares of the biopharmaceutical company’s stock worth $2,836,000 after buying an additional 489,532 shares during the last quarter. Institutional investors and hedge funds own 52.50% of the company’s stock.
Several analysts recently issued reports on TRVN shares. Oppenheimer set a $5.00 price target on Trevena and gave the company a “buy” rating in a report on Monday. HC Wainwright increased their price target on Trevena to $7.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Finally, Zacks Investment Research downgraded Trevena from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a report on Saturday, January 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Trevena currently has a consensus rating of “Buy” and an average target price of $7.06.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. equities analysts anticipate that Trevena Inc will post -0.96 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Trevena Inc (TRVN) Shares Bought by Virtu Financial LLC” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/03/14/trevena-inc-trvn-shares-bought-by-virtu-financial-llc.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding TRVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevena Inc (NASDAQ:TRVN).
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.